These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26034655)

  • 1. In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia.
    Gheith S; Saghrouni F; Bannour W; Ben Youssef Y; Khelif A; Normand AC; Piarroux R; Ben Said M; Njah M; Ranque S
    Springerplus; 2014; 3():19. PubMed ID: 26034655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC; Hsieh MI; Choi PC; Wu CJ
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.
    Vanathi M; Naik R; Sidhu N; Ahmed NH; Gupta N; Tandon R
    Indian J Ophthalmol; 2022 Dec; 70(12):4270-4283. PubMed ID: 36453329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents.
    Badiee P; Boekhout T; Zarei Mahmoudabadi A; Mohammadi R; Ayatollahi Mousavi SA; Najafzadeh MJ; Soltani J; Hashemi J; Diba K; Ghadimi-Moghadam A; Salimi-Khorashad AR; Shokohi T; Amin Shahidi M; Ghasemi F; Jafarian H
    Microbiol Spectr; 2022 Jun; 10(3):e0253921. PubMed ID: 35579442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.
    Badali H; Fakhim H; Zarei F; Nabili M; Vaezi A; Poorzad N; Dolatabadi S; Mirhendi H
    Mycopathologia; 2016 Apr; 181(3-4):235-40. PubMed ID: 26615417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
    Gürcan S; Tikveşli M; Eryildiz C; Evci C; Ener B
    Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre microdilution method].
    García-Martos P; García-Agudo L; Gutiérrez-Calzada J; Ruiz-Aragón J; Saldarreaga A; Marín P
    Enferm Infecc Microbiol Clin; 2005 Jan; 23(1):15-8. PubMed ID: 15701327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
    Al-Wathiqi F; Ahmad S; Khan Z
    BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal Susceptibility of the Aspergillus viridinutans Complex: Comparison of Two
    Lyskova P; Hubka V; Svobodova L; Barrs V; Dhand NK; Yaguchi T; Matsuzawa T; Horie Y; Kolarik M; Dobias R; Hamal P
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
    Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
    Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species distribution and antifungal susceptibility patterns of Aspergillus isolates from clinical specimens and soil samples in Mexico.
    Treviño-Rangel RJ; Villanueva-Lozano H; Bonifaz A; Castañón-Olivares LR; Andrade A; Becerril-García MA; Martínez-Reséndez MF; Ayala-Gaytán J; Montoya AM; González GM
    Med Mycol; 2021 Oct; 59(10):1006-1014. PubMed ID: 34021564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China.
    Jing R; Yang WH; Xiao M; Li Y; Zou GL; Wang CY; Li XW; Xu YC; Hsueh PR
    J Microbiol Immunol Infect; 2022 Apr; 55(2):282-290. PubMed ID: 33839057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
    Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
    Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
    Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
    Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.